BRCA1 and hyperinsulinemic hypoglycemia, familial, 4: This is consistent with the mounting volume of clinical and mechanistic studies highlighting the therapeutic responses of PARPi in a wider cohort of OV patients irrespective of BRCA1/2 status or HR‐mediated DNA repair deficiency.[36, 37] Our findings have helped to address the existing gap in understanding the targets correlated with sensitivity to PARPi in OV.